45,316 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, HoldingsChannel reports. The firm acquired 45,316 shares of the life sciences company’s stock, valued at approximately $6,065,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in Illumina during the 4th quarter valued at approximately $32,000. Assetmark Inc. lifted its position in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina in the 4th quarter valued at approximately $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina in the fourth quarter valued at approximately $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ILMN has been the subject of several recent research reports. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and reduced their target price for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Royal Bank of Canada dropped their price target on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a research note on Tuesday. Robert W. Baird reduced their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Finally, Citigroup dropped their target price on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.85.

Illumina Stock Down 4.3 %

Shares of NASDAQ ILMN opened at $70.30 on Wednesday. The firm’s 50-day moving average is $93.03 and its two-hundred day moving average is $123.78. The company has a market capitalization of $11.14 billion, a PE ratio of -9.15, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 12-month low of $69.38 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.